NASDAQ:STOK - Stoke Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $53.80
  • Forecasted Upside: 278.87 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$14.20
▼ -1.62 (-10.24%)

This chart shows the closing price for STOK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Stoke Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STOK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STOK

Analyst Price Target is $53.80
▲ +278.87% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The average price target is $53.80, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 278.87% upside from the last price of $14.20.

This chart shows the closing price for STOK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Stoke Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/22/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/19/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/17/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/18/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/16/2022Bank of AmericaLower Price TargetBuy$43.00 ➝ $40.00High
1/31/2022Jefferies Financial GroupInitiated CoverageBuy$50.00Medium
12/3/2021Bank of AmericaInitiated CoverageBuy$43.00High
11/22/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$41.00High
11/9/2021Cantor FitzgeraldReiterated RatingOverweightHigh
9/22/2021HC WainwrightReiterated RatingBuy$70.00High
8/17/2021Cantor FitzgeraldLower Price TargetOverweight$76.00 ➝ $68.00High
5/18/2021UBS GroupInitiated CoverageNeutral$35.00Low
5/10/2021WedbushUpgradeNeutral ➝ OutperformLow
3/10/2021Credit Suisse GroupBoost Price TargetOutperform$49.00 ➝ $58.00Medium
2/10/2021WedbushDowngradeOutperform ➝ NeutralLow
1/14/2021Needham & Company LLCBoost Price TargetPositive ➝ Buy$56.00 ➝ $65.00High
12/15/2020HC WainwrightReiterated RatingBuy$70.00Low
12/11/2020Needham & Company LLCBoost Price TargetBuy$48.00 ➝ $56.00Low
11/13/2020BTIG ResearchBoost Price TargetBuy$46.00 ➝ $68.00High
11/13/2020Credit Suisse GroupBoost Price TargetOutperform$42.00 ➝ $49.00Medium
10/23/2020Cantor FitzgeraldInitiated CoverageOverweight$49.00High
9/29/2020Needham & Company LLCInitiated CoverageBuy$42.00Low
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutralLow
8/11/2020HC WainwrightReiterated RatingBuy$30.00Medium
5/18/2020HC WainwrightReiterated RatingBuy$30.00High
3/23/2020CowenReiterated RatingBuyLow
12/17/2019WedbushInitiated CoverageOutperform$31.00Medium
12/9/2019HC WainwrightReiterated RatingBuy$30.00High
12/3/2019JPMorgan Chase & Co.Lower Price TargetOverweight$34.00 ➝ $33.00High
11/12/2019BTIG ResearchInitiated CoverageBuy$46.00High
10/25/2019HC WainwrightInitiated CoverageBuy$30.00High
8/15/2019CowenReiterated RatingBuyLow
7/15/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$35.00Medium
7/15/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$34.00Medium
7/15/2019CowenInitiated CoverageOutperform ➝ OutperformMedium
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/20/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/20/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/19/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/18/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/20/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/19/2022

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Stoke Therapeutics logo
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $14.20
Low: $13.68
High: $15.84

50 Day Range

MA: $19.39
Low: $12.69
High: $26.10

52 Week Range

Now: $14.20
Low: $12.59
High: $41.60

Volume

240,727 shs

Average Volume

323,373 shs

Market Capitalization

$555.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Stoke Therapeutics?

The following Wall Street research analysts have issued research reports on Stoke Therapeutics in the last twelve months: Bank of America Co., Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., and Zacks Investment Research.
View the latest analyst ratings for STOK.

What is the current price target for Stoke Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Stoke Therapeutics in the last year. Their average twelve-month price target is $53.80, suggesting a possible upside of 278.9%.
View the latest price targets for STOK.

What is the current consensus analyst rating for Stoke Therapeutics?

Stoke Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STOK will outperform the market and that investors should add to their positions of Stoke Therapeutics.
View the latest ratings for STOK.

How do I contact Stoke Therapeutics' investor relations team?

Stoke Therapeutics' physical mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company's listed phone number is (781) 430-8200 and its investor relations email address is [email protected] The official website for Stoke Therapeutics is www.stoketherapeutics.com. Learn More about contacing Stoke Therapeutics investor relations.